These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8973529)

  • 1. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies.
    Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S
    Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Gram GJ; Hemming A; Bolmstedt A; Jansson B; Olofsson S; Akerblom L; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):253-61. PubMed ID: 7832633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
    J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
    Gray ES; Moore PL; Pantophlet RA; Morris L
    J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
    Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
    Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    Trkola A; Purtscher M; Muster T; Ballaun C; Buchacher A; Sullivan N; Srinivasan K; Sodroski J; Moore JP; Katinger H
    J Virol; 1996 Feb; 70(2):1100-8. PubMed ID: 8551569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
    Grimaila RJ; Fuller BA; Rennert PD; Nelson MB; Hammarskjöld ML; Potts B; Murray M; Putney SD; Gray G
    J Virol; 1992 Apr; 66(4):1875-83. PubMed ID: 1548744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
    Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
    J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer.
    Schønning K; Jansson B; Olofsson S; Nielsen JO; Hansen JS
    Virology; 1996 Apr; 218(1):134-40. PubMed ID: 8615015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.
    Drummer HE; Hill MK; Maerz AL; Wood S; Ramsland PA; Mak J; Poumbourios P
    PLoS Pathog; 2013; 9(4):e1003218. PubMed ID: 23592978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.